Screening of 14C-polyamines in the AT3B-1 rat prostate tumor model: The search for a new PET prostate imaging agent

In Vivo

Volumn 21, Issue 5, 2007, Pages 823-828

  Palakurthi, Srinath ^a   McQuarrie, S A ^b   Suresh, M R ^b  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Polyamines; Positron emission tomography (PET); Prostatic neoplasms; Radiopharmaceuticals; Radiopharmacology

Indexed keywords

CARBON 14; CARBON DIOXIDE; DIAGNOSTIC AGENT; ORNITHINE C 14; POLYAMINE C 14; PUTRESCINE C 14; RADIOPHARMACEUTICAL AGENT; SPERMIDINE C 14; SPERMINE C 14; TRACER; UNCLASSIFIED DRUG; CARBON; POLYAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; COPENHAGEN RAT; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG SCREENING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; IN VIVO STUDY; LIQUID SCINTILLATION COUNTING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY; RAT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE MODEL; METHODOLOGY; PROSTATE TUMOR;

ANIMALS; CARBON RADIOISOTOPES; DISEASE MODELS, ANIMAL; MALE; NEOPLASM TRANSPLANTATION; POLYAMINES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RATS;

EID: 35649028662     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer Statistics. 2003. CA Cancer J Clin 53(1): 5-26, 2003.
2. Yu KK and Hawkins H: Imaging prostate cancer. Radiol Clin North Am 38: 59-85, 2000.
3. Nudell DM, Wefer AE, Hricak H and Carroll PR: Imaging for recurrent prostate cancer. Radiol Clin North Am 38: 213-229, 2000.
4. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP and Pomper MG: Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging experimental models of prostate cancer. Clin Cancer Res 11(11): 4022-4028, 2005.
5. Rosenthal DI: Radiologic diagnosis of bone metastases. Cancer 80(Suppl): 1595-1607, 1997.
6. Hayword SJ, McIvor J, Burdge AH, Jewkes RF and Williams G: Staging of prostatic carcinoma with radionuclide bone scintigraphy and lymphography. Br J Radiol 60: 79-81, 1987.
7. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J and Bakale G: Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 56: 988-993, 2000.
8. Hain SF and Maisey MN: Positron emission tomography for urological tumors. Br J Urol Int 92: 159-164, 2003.
9. Hoh CK, Schiepers C, Seltzer M, Gambhir SS, Silverman DH, Czernin J, Maddahi J and Phelps ME: PET in oncology: will it replace the other modalities? Semin Nucl Med 27: 94-106, 1997.
10. Jerusalem G, Hustinx R, Beguin Y and Fillet G: PET scan imaging in oncology. Eur J Cancer 39: 1525-1534, 2003.
11. Langsteger W, Heinisch M and Fogelman I: The role of fluorodeoxyglucose, (18)F-dihydroxyphenylalanine, (18)F-choline, and (18)F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36(1): 73-92, 2006.
12. Sanz G, Rioja J, Zudaire J, Berian JM and Richter JA: PET and prostate cancer. World J Urol 22(5): 351-352, 2004.
13. Giorgetti A, Volterrani D and Mariani G: Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose. Radiologia Medica 103: 293-318, 2002.
14. Sung J, Espiritu JI, Segall GM and Terris MK: Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. Br J Urol International 92: 24-27, 2003.
15. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME and Belldegrun A: Positron emission tomography in urological oncology. J Urol 159: 347-356, 1998.
16. Liu IJ, Zafar MB, Lai YH, Segall GM and Terris MK: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57: 108-111, 2001.
17. Salminen E, Hogg A, Binns D, Frydenberg M and Hicks R: Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 41: 425-429, 2002.
18. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W and Mensink HJ: Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urology 42: 18-23, 2002.
19. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei DV, De Cobelli F, Del Maschio A, Rocco F, Rigatti P and Fazio F: Value of 11C-choline-positron emission tomography for re-staging prostate cancer: a comparison with 18F fluorodeoxyglucose-positron emission tomography. J Urol 169: 1337-1340, 2003.
20. 18F-fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168: 273-280, 2002.
21. 18F-labelled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61: 110-117, 2001.
22. 11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imag 32(6): 668-673, 2005.
23. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74(3): 214-220, 2005.
24. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43: 46-55, 2002.
25. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, Takahashi N, Welch MJ and Fujibayashi Y: Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28: 117-122, 2001.
26. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imag 30: 607-611, 2003.
27. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44: 549-555, 2003.
28. Schipper RG, Romijn JC, Cuijpers VMJI and Verhofstad AAJ: Polyamines and prostate cancer. Biochem Soc Trans 31(2): 375-380, 2003.
29. Scalabrino G and Ferioli ME: Polyamines in mammalian tumors. Adv Cancer Res 35: 151-168, 1982.
30. Carnellakis ZN and Williams AHG: Polyamines in mammalian biology and medicine. Perspect Biol Med 22: 421-4531, 1979.
31. Pegg AE and McCann PP: Polyamine metabolism and function. Am J Physiol 243: 212-221, 1982.
32. Jänne J, Pösö H and Raina A: Polyamines in rapid growth and cancer. Biochim Biophys Acta 473: 241-293, 1978
33. Pegg AE: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48: 759-774, 1988.
34. Buffkin C, Webber MM, Davidson WD, Bassist L F and Verma RC: Ornithine as a possible marker of Cancer. Cancer Res 38: 3225-3232, 1978
35. Coleman CS, Hu G and Pegg AE: Putrescine biosynthesis in mammalian tissues. Biochem J 379: 849-855, 2004.
36. 14C]ornithine. Nucl Med Biol 15(2): 119-122, 1988.
37. 14C]ornithine. Nucl Med Biol 17: 597-600, 1990.
38. Welch MJ, Coleman RE and Straatmann MG: Carbon-11 labeled methylated polyamine analogs: uptake in prostate and tumor in animal models. J Nucl Med 18: 337-342, 1977.
39. 11C]2-deoxy-D-glucose. J Nucl Med 28: 1251-1261, 1987.
40. McPherson DW, Fowler JS, Wolf AP, Arnett CD, Brodie JD and Volkow N: Synthesis and biodistribution of no-carrier-added [1-11C]putrescine. J Nucl Med 26: 1186-1189, 1985.
41. Hwang D, Lang L, Mathias CJ, Kadmon D and Welch MJ: N-3 [18F] fluoropropyl putrescine as a potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med 30: 1205-1210, 1989.
42. Srinath P, McQuarrie SA and Suresh MR: Comparative uptake of polyamines by prostate and non-prostate cancer cell lines. Nucl Med Biol 29: 497-503, 2002.
43. 18F]fluoropropyl)putrescine. Int J Rad Appl Instrum B 17: 525-532, 1990.
44. Kadmon D: Chemoprevention in prostate cancer. The role of difluoromethylornithine (DFMO). J Cell Biochem Supp. 16 H: 122-127, 1992.
45. Liu X, Wang L, Lin Y, Teng Q, Zhao C, Hu H and Chi W: Ornithine decarboxylase activity and its gene expression are increased in benign hyperplastic prostate. Prostate 43: 83-87, 2000.